Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome
(World News Science)

Press release - No. 21/2018 Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome The Phase 3 registration trial has enrolled the first short bowel syndrome (SBS) patient with reduced or complete loss of intestinal function Glepaglutide has shown to increase intestinal absorption in patients with SBS Glepaglutide is a long-acting GLP-2 analog with potential for once-weekly dosing in an auto-injector pen Copenhagen, October 4 2018 - Zealand Pharma A/S (`Zealand`) (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the enrollment of...